Subconjunctival injection of triamcinolone acetonide in the management of corneal graft rejection and new vessels

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 607-612

  Athanasiadis, Ioannis ^a   De Wit, Deric ^a   Tsatsos, Michael ^a   Patel, Amit K ^a   Sharma, Anant ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

deep anterior lamellar keratoplasty; neovascularization; rejection; subconjunctival; Triamcinolone acetonide

Indexed keywords

BETAMETHASONE; CHLORAMPHENICOL; CORTISONE; DEXAMETHASONE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN ANTIBODY;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CASE REPORT; CATARACT; CONJUNCTIVA DISEASE; CORNEA EDEMA; CORNEA NEOVASCULARIZATION; DEEP ANTERIOR LAMELLAR KERATOPLASTY; DRUG POTENCY; GRAFT REJECTION; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; KERATOCONUS; KERATOPLASTY; MALE; MYDRIASIS; POSTOPERATIVE COMPLICATION; PTOSIS; SINGLE DRUG DOSE; SUTURE REMOVAL; TREATMENT RESPONSE; VISUAL ACUITY; WOUND HEALING IMPAIRMENT;

ADOLESCENT; CONJUNCTIVA; CORNEAL TRANSPLANTATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS; MALE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE;

EID: 84859018308     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011400073     Document Type: Article

References (51)

1. Birnbaum F, Reis A, Reinhard T. Topical immunosuppressives after penetrating keratoplasty. Ophthalmologe. 2007;104(5):381-387.
2. Bertelmann E, Reinhard T, Pleyer U. Current practice of immune prophylaxis and therapy in perforating keratoplasty: a survey of members of the Cornea Section of the German Ophthalmological Society. Ophthalmologe. 2003;100(12):1031-1035. (Pubitemid 38075997)
3. Koay PY, Lee WH, Figueiredo FC. Opinions onrisk factors and management of corneal graft rejection in the United Kingdom. Cornea. 2005;24(3):292-296. (Pubitemid 40418338)
4. Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns (2004). Cornea. 2006;25(3):286-290.
5. Awan MA, Agarwal PK, Watson DG, McGhee CN, Dutton GN. Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol. 2009;93(6):708-713.
6. Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide inocular therapeutics [review]. Surv Ophthalmol. 2007;52(5):503-522.
7. Peyman GA, Herbst R. Bacterial endophthalmitis: treatment with intraocular injection of gentamicin and dexamethasone. Arch Ophthalmol. 1974;91(5):416-418.
8. Sturman RM, Laval J, Sturman MF. Subconjunctival triamcinolone acetonide. Am J Ophthalmol. 1966;61(1):155-166.
9. Argenti D, Jensen BK, Hensel R, et al. A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration. J Clin Pharmacol. 2000;40(7):770-780.
10. Duguid IG, Boyd AW, Mandel TE. Adhesion molecules are expressed in the human retina and choroid. Curr Eye Res. 1992;11(suppl):153-159.
11. Panda A, Vanathi M, Kumar A, Dash Y, Priya S. Corneal graft rejection. Surv Ophthalmol. 2007;52:375-396. (Pubitemid 46901076)
12. Noble BA, Agrawal A, Collins C, Saldana M, Brogden PR, Zuberbuhler B. Deep anterior lamellar keratoplasty (DALK): visual outcome and complications for a heterogeneous group of corneal pathologies. Cornea. 2007;26(1):59-64. (Pubitemid 46041565)
13. Fontana L, Parente G, Tassinari G. Clinical outcomes after deep anterior lamellar keratoplasty using the big-bubble technique in patients with keratoconus. Am J Ophthalmol. 2007;143(1): 117-124.
14. McGhee CN. Pharmacokinetics ofophthalmic corticosteroids [review]. Br J Ophthalmol. 1992;76(11):681-684.
15. Coles RS. Steroid therapy inuveitis. Int Ophthalmol Clin. 1966;6(4):869-901.
16. Coles RS, Krohn DL, Breslin H, Braunstein R. Depo-Medrol in treatment of inflammatory diseases. Am J Ophthalmol. 1962;54: 407-411.
17. Derendorf H, Möllmann H, Grüner A, Haack D, Gyselby G. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther. 1986;39(3):313-317. (Pubitemid 16113640)
18. Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology. 2002;109(10):1887-1891.
19. Francis BA, Chang EL, Haik BG. Particle size and drug interactions of injectable corticosteroids used in ophthalmic practice. Ophthalmology. 1996;103(11):1884-1888. (Pubitemid 26403744)
20. Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol. 2004;37(3):560-562. (Pubitemid 38328652)
21. Albini TA, Zamir E, Read RW, Smith RE, See RF, Rao NA. Evaluation of subconjunctival triamcinolone for nonnecrotizing anterior scleritis. Ophthalmology. 2005;112(10):1814-1820. (Pubitemid 41400021)
22. Croasdale CR, Brightbill FS. Subconjunctival corticosteroid injections for nonnecrotizing anterior scleritis. Arch Ophthalmol. 1999;117(7):966-968. (Pubitemid 29330788)
23. Paris Fdos S, de Farias CC, Melo GB, Dos Santos MS, Batista JL, Gomes JA. Postoperative subconjunctival corticosteroid injection to prevent pterygium recurrence. Cornea. 2008;27(4):406-410. (Pubitemid 351591476)
24. Shen YC, Wang CY, Tsai HY, Lee YF. Supratarsal triamcinolone injection in the treatment of superior limbic keratoconjunctivitis. Cornea. 2007;26(4):423-426.
25. Giangiacomo J, Dueker DK, Adelstein E. The effect of preoperative subconjunctival triamcinolone administration on glaucoma filtration: I. Trabeculectomy following subconjunctival triamcinolone. Arch Ophthalmol. 1986;104(6):838-841. (Pubitemid 16114929)
26. Chee E, Chee SP. Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease: a case series. Eye. 2008;22(2):311-315. (Pubitemid 351266477)
27. Athanasiadis Y, Novitskaya E, Nithyanandrajah GA, Sharma A. Subconjunctival triamcinolone for the treatment of corneal graft rejection and new vessels. Cont Lens Anterior Eye. 2009;32(1):31-32.
28. Costa DC, de Castro RS, Kara-Jose N. Case-control study of subconjunctival triamcinolone acetonide injection vs intravenous methylprednisolone pulse in the treatment of endothelial corneal allograft rejection. Eye. 2009;23(3):708-714.
29. Murata M, Shinji S, Horiuchi S, Taira M. Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2006;244(2):205-209.
30. Carmichael TR. Corneal angiogenesis. In: Tombran-Tink J, Barnstable CJ, eds. Ocular Angiogenesis: Diseases, Mechanisms, and Therapeutics. Totowa, NJ: Humana; 2006:45-72.
31. Bernstein HN, Scwhartz B. Effects of long-term systemic steroids on ocular pressure and tonographic values. Arch Ophthalmol. 1962;68:742-753.
32. Cantrill HL, Palmberg PF, Zink HA, Waltman SR, Podos SM, Becker B. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975;79(6): 1012-1017.
33. Kalina PH, Erie JC, Rosenbaum L. Biochemical quantification of triamcinolone in subconjunctival depots. Arch Ophthalmol. 1995;113(7):867-869.
34. Kalina RE. Increased intraocular pressure following subconjunctival corticosteroid administration. Arch Ophthalmol. 1969;81(6):788-790.
35. Mills DW, Siebert LF, Climenhaga DB. Depot triamcinoloneinduced glaucoma. Can J Ophthalmol. 1986;21:150-152.
36. Hanson RJ, Downes S. Conservative management of refractory steroid-induced glaucoma following anterior subtenon steroid injection. Clin Experiment Ophthalmol. 2007;35(2):197-198. (Pubitemid 46390818)
37. Herschler J. Intractable intraocular hypertension induced by repository triamcinolone acetonide. Am J Ophthalmol. 1972;74(3): 501-504.
38. Herschler J. Increased intraocular pressure induced by repository corticosteroids. Am J Ophthalmol. 1976;82(1):90-93.
39. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: areview of the literature [review]. Eye. 2006;20(4):407-416.
40. Ferry AP, Harris WP, Nelson MH. Histopathologic features of subconjunctivally injected corticosteroids. Am J Ophthalmol. 1987;103(5):716-718. (Pubitemid 17070036)
41. Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the longterm risk of cataract. Ophthalmology. 2009;116(4):652-657.
42. James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007;23(5):403-420.
43. Agrawal S, Agrawal J, Agrawal TP. Conjunctival ulceration following triamcinolone injection. Am J Ophthalmol. 2003;136(3): 539-540. (Pubitemid 37101254)
44. Rubinstein A, Hanson RJ, Chen SD, Porter N, Downes SM. Conjunctival ischaemia subsequent toposterior subtenon's triamcinolone acetonide injection. Eye. 2006;20(3):388-389.
45. Chan CK, Mohamed S, Tang EW, Shanmugam MP, Chan NR, Lam DS. Encapsulated triamcinolone cyst after subtenon injection. Clin Experiment Ophthalmol. 2006;34(4):360-362. (Pubitemid 44137555)
46. Gaudio PA. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation [review]. Ocul Immunol Inflamm. 2004;12(3):169-192. (Pubitemid 39424881)
47. Ugarte M, Williamson TH. Intravitreal steroids: from mechanisms to clinical practice. Curr Med Lit. 2007;17(1):1-9.
48. Harooni H, Reddy V, Root T, Ambati B. Bevacizumab for graft rejection. Ophthalmology. 2007;114(10):1950.
49. Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33(11): 1991-1993. (Pubitemid 47615364)
50. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2007;91(6):804-807. (Pubitemid 46846656)
51. Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw Hill; 2001.